A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patients

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Obuya S, Elkholy A, Avuthu N, Behring M, Bajpai P, Agarwal S, Kim HG, El-Nikhely N, Akinyi P, Orwa J, Afaq F, Abdalla M, Michael A, Farouk M, Bateman LB, Fouad M, Saleh M, Guda C, Manne U, Arafat W
Journal
Journal of gastrointestinal oncology
Year
2022
Keywords:
Colorectal cancer (CRC), Faecalibacterium prausnitzii, Kenya, Prevotella copri, microbiome
BACKGROUND: Colorectal cancer (CRC) is the fifth most diagnosed cancer in Sub-Saharan Africa. In Kenya, CRC incidence rates tripled from 1997 to 2017. In the Moi Teaching and Referral Hospital, Moi University, there has been an increase in CRC cases, notably for younger patients. A suggested pathobiology for this increase is gut microbiome dysbiosis. Since, for the Kenyan CRC patient population, microbiome studies are rare, there is a need for a better understanding of how microbiome dysbiosis influences CRC epidemiology in Kenya. In this single-center study, the focus was on profiling the gut microbiome of Kenyan CRC patients and healthy volunteers and evaluating associations between microbiome profiles and the age of CRC patients. METHODS: The gut mucosa-associated microbiome of 18 CRC patients and 18 healthy controls were determined by 16S rRNA sequencing and analyzed for alpha and beta diversity, differential abundance, and microbial metabolic profiling. RESULTS: Alpha diversity metrics showed no significant differences, but beta diversity metrics showed dissimilarities in the microbial communities between CRC patients and healthy controls. The most underrepresented species in the CRC group were Prevotella copri (P. copri) and Faecalibacterium prausnitzii (F. prausnitzii), although Bacteroides fragilis (B. fragilis) and Prevotella nigrescens were overrepresented (linear discriminant analysis, LDA score >2, P<0.05). Also, for CRC patients, significant metagenomic functional alterations were evident in microbial glutamate metabolic pathways (L-glutamate degradation VIII was enriched, and L-glutamate and L-glutamine biosynthesis were diminished) (P<0.05, log2 Fold Change >1). Moreover, the microbiome composition was different for patients under 40 years of age compared to older patients (LDA score >2, P<0.05). CONCLUSIONS: Microbiome and microbial metabolic profiles of CRC patients are different from those of healthy individuals. CRC microbiome dysbiosis, particularly P. copri and F. prausnitzii depletion and glutamate metabolic alterations, are evident in Kenyan CRC patients.

Experiment 1


Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Subjects

Location of subjects
Kenya
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Colon Hindgut,Large bowel,Posterior intestine,Colon,colon
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy Control
Group 1 name Corresponds to the case (exposed) group for case-control studies
CRC Patients
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
patients with Colorectal Cancer
Group 0 sample size Number of subjects in the control (unexposed) group
18
Group 1 sample size Number of subjects in the case (exposed) group
18
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
4 weeks

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2.0

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged
Richness Number of species
unchanged

Signature 1

Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Source: Figure 2

Description: Bar graph of LEfSe analysis CRC vs. healthy controls

Abundance in Group 1: increased abundance in CRC Patients

NCBI Quality ControlLinks
Mycoplasma
Mycoplasmatales
Campylobacter ureolyticus
Mycoplasmataceae
Peptostreptococcus anaerobius
Rhodospirillales
Mogibacterium
Anaerococcus
Peptoniphilus
Lactobacillus iners
Mobiluncus
Solobacterium moorei
Helicobacteraceae
Flexispira
Moryella indoligenes
Moryella
1_681_68
Clostridium
Schwartzia
Sporobacterium sp. WAL 1855D
Veillonella dispar
Veillonella parvula
Peptostreptococcus
p_75_a5p_75_a5
Staphylococcaceae
Staphylococcus
Parvimonas
Bacillales
Tissierellaceae
Porphyromonas
Prevotella nigrescens
Fusobacterium
Bacteroides fragilis

Revision editor(s): Ifeanyisam

Signature 2

Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Source: Figure 2

Description: Bar graph of LEfSe analysis CRC vs. healthy controls.

Abundance in Group 1: decreased abundance in CRC Patients

NCBI Quality ControlLinks
Actinomycetales
Alcaligenaceae
Alphaproteobacteria
Bacteroides
Bacteroides eggerthii
Burkholderiales
Collinsella
Collinsella aerofaciens
Coriobacteriales
Coriobacteriia
Cyanobacteriota
Dorea formicigenerans
Erysipelotrichaceae
Eubacterium
Faecalibacterium
Faecalibacterium prausnitzii
Haemophilus parainfluenzae
Holdemanella biformis
Parabacteroides
Pasteurellaceae
Pasteurellales
Roseburia
Roseburia faecis
Segatella copri
Sutterella
4COd_24COd_2
YS2YS2
[Ruminococcus] lactaris

Revision editor(s): Ifeanyisam

Experiment 2


Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
CRC patients under 40 years of age
Group 1 name Corresponds to the case (exposed) group for case-control studies
CRC Patients over 40 years of age
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with Colorectal Cancer over 40 years of age
Group 0 sample size Number of subjects in the control (unexposed) group
8
Group 1 sample size Number of subjects in the case (exposed) group
10

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Source: Figure 3

Description: Bar graph of LEfSe analysis for CRC patients under 40 years of age vs. over 40 years of age.

Abundance in Group 1: increased abundance in CRC Patients over 40 years of age

NCBI Quality ControlLinks
Bacteroides ovatus
Thomasclavelia ramosa
[Clostridium] symbiosum

Revision editor(s): Ifeanyisam

Signature 2

Needs review

Curated date: 2024/10/29

Curator: Ifeanyisam

Revision editor(s): Ifeanyisam

Source: Figure 3

Description: Bar graph of LEfSe analysis for CRC patients under 40 years of age vs. over 40 years of age.

Abundance in Group 1: decreased abundance in CRC Patients over 40 years of age

NCBI Quality ControlLinks
Segatella copri
Bacteria
Oxalobacteraceae
Ligilactobacillus salivarius
Herbaspirillum
Enhydrobacter
Lysobacteraceae
Lysobacterales

Revision editor(s): Ifeanyisam